Halozyme Therapeutics reported $161.66M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 128.58M 3.32M
Agios Pharmaceuticals AGIO:US USD 3M 2.15M
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amarin AMRN:US USD 65.94M 7.31M
Amgen AMGN:US USD 5.06B 20M
Baxter International BAX:US USD 1.15B 310M
Cara Therapeutics CARA:US USD 7.76M 15.24M
Eli Lilly And LLY:US USD 5.36B 305M
Esperion Therapeutics ESPR:US USD 12.47M 2.81M
Halozyme Therapeutics HALO:US USD 161.66M 43.24M
Intercept Pharmaceuticals ICPT:US USD 77.16M 5.72M
Intra Cellular Therapies ITCI:US USD 66.02M 15.09M
Intrexon XON:US USD 15.14M 14.04M
IONIS PHARMACEUT IONS:US USD 158.25M 29.21M
JAZZ PHA JAZZ:US USD 806.99M 1.68M
Mannkind MNKD:US USD 15.36M 9.39M
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Peregrine Pharmaceuticals PPHM:US USD 9.12M 2.13M
Pfizer PFE:US USD 16.55B 2.52B
United Therapeutics UTHR:US USD 478.8M 41.6M